Price$0.62-0.48 (-43.49%)
2026-04-142026-07-17
News · 26 weeks67+275%
2026-01-182026-07-12
Mix3890d
- Insider14(37%)
- SEC Filings12(32%)
- Other7(18%)
- Earnings3(8%)
- Leadership2(5%)
Latest news
25 items- INSIDERNew insider Desai Arjun Jj claimed no ownership of stock in the company (SEC Form 3)3 - Longeveron Inc. (0001721484) (Issuer)
- SECLongeveron Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Longeveron Inc. (0001721484) (Filer)
- INSIDERNew insider Ascheim Deborah claimed no ownership of stock in the company (SEC Form 3)3 - Longeveron Inc. (0001721484) (Issuer)
- INSIDERNew insider Cann Leah Rush claimed no ownership of stock in the company (SEC Form 3)3 - Longeveron Inc. (0001721484) (Issuer)
- PRLongeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s DiseasePoster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC) entitled "Laromestrocel Stabilizes Brain Inflammation In Key Alzheimer’s Disease Gray And White Matter Regions As Assessed Using Free Water MRI" presented at July 13th In Person Poster Presentation SessionResults support a clinically relevant and long-lasting anti-inflammatory mechanism of action of laromestrocel in gray and white matter of the brain, indicate potential blood biomarker correlates with clinical outcomes, and support continued clinical development of laromestrocel for Alzheimer’s diseaseLongeveron has received U.S. FDA RMAT designation for its Alzheimer’s disease program and has aligned on
- SECSEC Form S-8 filed by Longeveron Inc.S-8 - Longeveron Inc. (0001721484) (Filer)
- INSIDERChief Scientific Officer Hare Joshua was granted 600,000 units of Class B Common Stock, increasing direct ownership by 83% to 1,321,796 units (SEC Form 4)4 - Longeveron Inc. (0001721484) (Issuer)
- SECLongeveron Inc. filed SEC Form 8-K: Leadership Update8-K - Longeveron Inc. (0001721484) (Filer)
- INSIDERChief Executive Officer Willard Stephen H covered exercise/tax liability with 18,046 shares, decreasing direct ownership by 2% to 771,681 units (SEC Form 4) (tax liability)4 - Longeveron Inc. (0001721484) (Issuer)
- INSIDERChief Financial Officer Locklear Lisa covered exercise/tax liability with 22,505 shares, decreasing direct ownership by 5% to 443,181 units (SEC Form 4) to satisfy tax liability4 - Longeveron Inc. (0001721484) (Issuer)
- INSIDERChief Medical Officer Agafonova Nataliya covered exercise/tax liability with 22,505 shares, decreasing direct ownership by 5% to 430,914 units (SEC Form 4) (tax withholding)4 - Longeveron Inc. (0001721484) (Issuer)
- INSIDERCTO & SVP of CMC Blass Devin covered exercise/tax liability with 15,808 shares, decreasing direct ownership by 4% to 425,735 units (SEC Form 4) (for withholding tax)4 - Longeveron Inc. (0001721484) (Issuer)
- INSIDERGeneral Counsel, Secretary Lehr Paul T covered exercise/tax liability with 13,143 shares, decreasing direct ownership by 2% to 575,423 units (SEC Form 4) (for tax liability)4 - Longeveron Inc. (0001721484) (Issuer)
- SECLongeveron Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Longeveron Inc. (0001721484) (Filer)
- PRLongeveron® Appoints Marie Washburn as Chief Financial OfficerMs. Washburn has over 20 years of experience in leadership roles in the pharmaceutical and biotech sectorsCorporate focus on delivering top-line results from the Phase 2b clinical trial evaluating its stem cell therapy in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 MIAMI, July 06, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Marie Washburn to the Company’s executive leadership team in the role of Senior Vice President and Chief Financial Officer ("CFO"), p
- PRNew Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer's Disease Accepted for Poster Presentation at the 2026 Alzheimer's Association International Conference (AAIC)MIAMI, June 18, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that additional analysis of data from the Phase 2a clinical trial evaluating its stem cell therapy laromestrocel in mild Alzheimer's disease has been accepted for Poster Presentation at the 2026 Alzheimer's Association International Conference® (AAIC®), to be held July 12-15, 2026 in London, United Kingdom and online. Poster Presentation (Exhibit Hall)Date:Monday, July 13, 2026Time:7:30am – 4:15pm BSTSession:In-Person Posters Tuesday; Drug Development: HumanTopic:
- PRLongeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has been granted Small or Medium-sized Enterprise (SME) status by the European Medicines Agency (EMA), which offers significant benefits leading up to and following drug regulatory approval. The SME program is an initiative by the EMA to address the particular needs of small and medium size companies developing medicinal products in Europe. Companies that are granted SME designation are able to seek scientific advice, protocol assistance, and oth
- SECLongeveron Inc. filed SEC Form 8-K: Leadership Update8-K - Longeveron Inc. (0001721484) (Filer)
- PRLongeveron to Present at BIO International Convention 2026Company will highlight new and recently published data for stem cell therapy laromsestrocel Focus on potential partnership and strategic opportunities for Hypoplastic Left Heart Syndrome, Alzheimer's disease, Pediatric Dilated Cardiomyopathy and Aging-related FrailtyCorporate presentation Wednesday, June 24th at 2:15pm PT in Theater 4 MIAMI, June 04, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will participate in the BIO International Convention taking place June 22-25, 2026 at the San Diego Convention Ce
- SECSEC Form DEFA14A filed by Longeveron Inc.DEFA14A - Longeveron Inc. (0001721484) (Filer)
- SECSEC Form DEF 14A filed by Longeveron Inc.DEF 14A - Longeveron Inc. (0001721484) (Filer)
- PRLongeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key PrioritiesMIAMI, May 20, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company's Chief Executive Officer, Stephen Willard, issued the following letter to Longeveron stockholders. Dear Fellow Stockholders, I am delighted to join Longeveron at what I believe is an extraordinary time for the Company and our stem cell therapy, laromestrocel (Lomecel-B®). Longeveron is progressing through a significant inflection point in the Company's history. After taking on the CEO role in February, we embarked on two immediate critical task
- SECSEC Form SCHEDULE 13G filed by Longeveron Inc.SCHEDULE 13G - Longeveron Inc. (0001721484) (Subject)
- SECLongeveron Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Longeveron Inc. (0001721484) (Filer)
- PRLongeveron Announces 2026 First Quarter Financial Results and Provides Business UpdateOn track for August 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome, a rare pediatric disease and orphan-designated indicationClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, May 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic agi
LGVN FAQ
7 questionsWhat does Longeveron Inc. do?
Longeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was...Where does LGVN stock trade?
Longeveron Inc. (LGVN) is listed on NASDAQ.What sector and industry is LGVN in?
Longeveron Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Longeveron Inc. go public?
Longeveron Inc. (LGVN) completed its IPO in 2021.What are analysts saying about LGVN?
Longeveron Inc. has had 2 recent analyst actions on file. The most recent action was from ROTH MKM: Buy with a $1000.00 price target on 2024-12-06. Recent price targets range from $1000.00 to $2000.00.What companies are similar to LGVN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare LGVN side-by-side with any of them on Quantisnow.How can I track LGVN on Quantisnow?
Quantisnow aggregates Longeveron Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LGVN to receive live email and push alerts on every new disclosure.